ProVascTec
Private Company
Funding information not available
Overview
ProVascTec is an Irish preclinical biotech targeting critical limb ischemia (CLI) with a novel cell therapy approach. The company's technology aims to induce neovascularization via stem cell paracrine signaling, delivered via a proprietary device to create a 'natural bypass' around blocked arteries below the knee. Embedded within Europe's largest healthtech venture builder, NLC, the company is led by an experienced pharmaceutical manager and a serial inventor. Its strategy focuses on addressing a significant unmet medical need in peripheral artery disease where current interventions often fail.
Technology Platform
Off-the-shelf stem cell therapy leveraging paracrine signaling to induce neovascularization, combined with a proprietary local delivery device for percutaneous administration.
Opportunities
Risk Factors
Competitive Landscape
Competition includes other cell and gene therapy developers for PAD/CLI, advanced drug-eluting balloons and stents, and surgical techniques. The field is active but lacks a dominant biologic solution, leaving room for a differentiated approach like ProVascTec's if it demonstrates superior efficacy.